With December Approaching, Are More Turkish Price Cuts On The Way?
This article was originally published in The Pink Sheet Daily
Executive Summary
The government of the world's 12th-largest pharmaceutical market has enforced steep price cuts on drugs in each of the last two years, both times in December.
You may also be interested in...
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts
Boehringer Threatens Turkish Exit Due To Price Cuts
German drug maker Boehringer Ingelheim GMBH, dismayed by profit declines caused by a series of price cut measures enforced by the Turkish government, has indicated it is considering quitting the Turkish market, but it still hopes to continue research and investment in one of the fastest growing pharmaceutical markets